225 related articles for article (PubMed ID: 22869054)
1. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials.
Celio L; Bonizzoni E; Bajetta E; Sebastiani S; Perrone T; Aapro MS
Support Care Cancer; 2013 Feb; 21(2):565-73. PubMed ID: 22869054
[TBL] [Abstract][Full Text] [Related]
2. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.
Celio L; Frustaci S; Denaro A; Buonadonna A; Ardizzoia A; Piazza E; Fabi A; Capobianco AM; Isa L; Cavanna L; Bertolini A; Bichisao E; Bajetta E;
Support Care Cancer; 2011 Aug; 19(8):1217-25. PubMed ID: 20574663
[TBL] [Abstract][Full Text] [Related]
3. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.
Celio L; Denaro A; Agustoni F; Bajetta E
J Support Oncol; 2012; 10(2):65-71. PubMed ID: 22005217
[TBL] [Abstract][Full Text] [Related]
4. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
Caputo R; Cazzaniga ME; Sbrana A; Torrisi R; Paris I; Giordano M; Montesarchio V; Guarneri V; Amaducci L; Bilancia D; Cilenti G; Fabi A; Collovà E; Schirone A; Bonizzoni E; Celio L; De Placido S; De Laurentiis M
BMC Cancer; 2020 Mar; 20(1):232. PubMed ID: 32188417
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
Boccia R; Grunberg S; Franco-Gonzales E; Rubenstein E; Voisin D
Support Care Cancer; 2013 May; 21(5):1453-60. PubMed ID: 23354552
[TBL] [Abstract][Full Text] [Related]
6. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
[TBL] [Abstract][Full Text] [Related]
7. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
[TBL] [Abstract][Full Text] [Related]
9. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
10. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
[TBL] [Abstract][Full Text] [Related]
11. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
Rozzi A; Nardoni C; Corona M; Restuccia MR; Fabi A; Bria E; Minniti G; Lanzetta G
Support Care Cancer; 2011 May; 19(5):697-701. PubMed ID: 20467757
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
Matsumoto K; Takahashi M; Sato K; Osaki A; Takano T; Naito Y; Matsuura K; Aogi K; Fujiwara K; Tamura K; Baba M; Tokunaga S; Hirano G; Imoto S; Miyazaki C; Yanagihara K; Imamura CK; Chiba Y; Saeki T
Cancer Med; 2020 May; 9(10):3319-3327. PubMed ID: 32168551
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
Aapro M; Fabi A; Nolè F; Medici M; Steger G; Bachmann C; Roncoroni S; Roila F
Ann Oncol; 2010 May; 21(5):1083-8. PubMed ID: 20080830
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
15. Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.
Lorusso V; Giampaglia M; Petrucelli L; Saracino V; Perrone T; Gnoni A
Support Care Cancer; 2012 Dec; 20(12):3241-6. PubMed ID: 22534864
[TBL] [Abstract][Full Text] [Related]
16. Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Wenzell CM; Berger MJ; Blazer MA; Crawford BS; Griffith NL; Wesolowski R; Lustberg MB; Phillips GS; Ramaswamy B; Mrozek E; Flynn JM; Shapiro CL; Layman RM
Support Care Cancer; 2013 Oct; 21(10):2845-51. PubMed ID: 23748485
[TBL] [Abstract][Full Text] [Related]
17. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
18. A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy.
Segawa Y; Aogi K; Inoue K; Sano M; Sekine I; Tokuda Y; Isobe H; Ogura T; Tsuboi M; Atagi S;
Ann Oncol; 2009 Nov; 20(11):1874-80. PubMed ID: 19605507
[TBL] [Abstract][Full Text] [Related]
19. Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients.
Brugnatelli S; Gattoni E; Grasso D; Rossetti F; Perrone T; Danova M
Tumori; 2011; 97(3):362-6. PubMed ID: 21789017
[TBL] [Abstract][Full Text] [Related]
20. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
Schwartzberg L; Karthaus M; Rossi G; Rizzi G; Borroni ME; Rugo HS; Jordan K; Hansen V
Cancer Med; 2019 May; 8(5):2064-2073. PubMed ID: 30968588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
